RecruitingNCT07117136

Blinatumomab Consolidation in Real World

Real World Outcomes of Blinatumomab Consolidation in Patients With B-cell Acute Lymphoblastic Leukemia

Sponsor

Medical College of Wisconsin

Enrollment

200 participants

Start Date

Aug 28, 2025

Study Type

OBSERVATIONAL

Conditions

B-Cell Acute Lymphoblastic Leukaemia

Summary

This will be a multi-center registry for patients with B-ALL. Patient data will be collected both retrospectively and prospectively. The data forms and surveys will be built and managed through REDCap, a secure web application managed by the Clinical \& Translational Science Institute.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This real-world study is collecting data on how blinatumomab — an immune-based treatment that connects immune cells to leukemia cells to destroy them — is being used as consolidation therapy in patients with B-cell acute lymphoblastic leukemia (B-ALL) in routine clinical practice. **You may be eligible if...** - You are 18 or older - You have been diagnosed with B-ALL on or after December 1, 2023 - You were not enrolled in an interventional clinical trial that provided blinatumomab - You or your representative are willing and able to provide informed consent **You may NOT be eligible if...** - There are no specific exclusion criteria listed for this study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07117136

Related Trials

A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab

NCT074223372 locations